ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.17%
US Dollar vs MXN
16.61444
-0.04%
Brent Oil
82.195
-0.30%
Bitcoin
70,042.11
-0.12%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Kronos Bio Inc (KRON)

  7. Kronos Bio Inc (KRON) Noticias

KRON

Kronos Bio (KRON)

Kronos Bio Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:KRON
FechaHoraFuenteTítuloSímboloCompañía
21/05/202415:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRONKronos Bio Inc
21/05/202407:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
21/05/202407:15GlobeNewswire Inc.Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer NASDAQ:KRONKronos Bio Inc
09/05/202415:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
09/05/202415:05GlobeNewswire Inc.Kronos Bio Reports First-Quarter 2024 Financial ResultsNASDAQ:KRONKronos Bio Inc
24/04/202415:01GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
21/03/202406:05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
07/03/202415:05GlobeNewswire Inc.Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash RunwayNASDAQ:KRONKronos Bio Inc
05/03/202415:44GlobeNewswire Inc.Kronos Bio To Present Three Posters at AACR 2024 Annual MeetingNASDAQ:KRONKronos Bio Inc
27/02/202415:05GlobeNewswire Inc.Kronos Bio Announces Participation in 44th Annual Cowen Health Care ConferenceNASDAQ:KRONKronos Bio Inc
23/02/202419:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
23/02/202419:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
18/12/202315:06GlobeNewswire Inc.Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development CandidateNASDAQ:KRONKronos Bio Inc
04/12/202307:00GlobeNewswire Inc.Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:KRONKronos Bio Inc
27/11/202315:05GlobeNewswire Inc.Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:KRONKronos Bio Inc
13/11/202315:05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
02/11/202315:05GlobeNewswire Inc.Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 StudyNASDAQ:KRONKronos Bio Inc
02/11/202311:00GlobeNewswire Inc.Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual MeetingNASDAQ:KRONKronos Bio Inc
27/10/202307:00GlobeNewswire Inc.Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual MeetingNASDAQ:KRONKronos Bio Inc
13/10/202311:30GlobeNewswire Inc.Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTCNASDAQ:KRONKronos Bio Inc
04/10/202315:05GlobeNewswire Inc.Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13NASDAQ:KRONKronos Bio Inc
17/08/202307:00GlobeNewswire Inc.Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate DevelopmentNASDAQ:KRONKronos Bio Inc
08/08/202315:05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
26/06/202316:19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KRONKronos Bio Inc
26/06/202315:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KRONKronos Bio Inc
06/06/202307:00GlobeNewswire Inc.Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality AssuranceNASDAQ:KRONKronos Bio Inc
01/06/202315:05GlobeNewswire Inc.Kronos Bio Announces Participation in Upcoming Investor ConferencesNASDAQ:KRONKronos Bio Inc
30/05/202315:36Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:KRONKronos Bio Inc
10/05/202315:05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
27/04/202315:36Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:KRONKronos Bio Inc
 Showing the most relevant articles for your search:NASDAQ:KRON

Su Consulta Reciente

NASDAQ
GOOGL
Alphabet
NYSE
DIS
Walt Disney
USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
US500
US 500
FX
EURMXN
Euro vs MXN
NASDAQ
AMZN
Amazon.com
USI
USTECH100
US Tech 100
NASDAQ
NVDA
NVIDIA
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLE
Energy Select Sector SPDR
CCOM
OILBRENT
Brent Oil
NASDAQ
MSFT
Microsoft
NYSE
KO
Coca Cola
USOTC
ADDYY
Adidas (QX)
USOTC
BASFY
BASF (QX)
AMEX
XLV
Health Care Select Sector
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados